Anti-tumor effect of novel plasma medicine caused by lactate
Nagoya University
Now, a research team based at Nagoya University used plasma to activate Ringer's solution, a salt solution with existing therapeutic functions, and showed that its lactate component had anti-tumor effects.
Previous work by the researchers developed plasma-activated cell culture medium as a form of chemotherapy, but selected Ringer's solution in the present work because of its simpler composition and likelihood of forming less complex reaction products. Ringer's lactate solution (Lactec) was irradiated with plasma for 3-5 minutes, after which it demonstrated anti-tumor effects on brain tumor cells.
Other plasma-activated solutions have previously been shown to induce reactive oxygen species within cells, but these were not detected in plasma-activated Lactec (PAL)-treated cells, suggesting an alternative mechanism triggered cell death. Analysis of PAL identified high levels of hydrogen peroxide, which is a known anti-tumor factor and the probable cause of cell death.
Lactec contains lactate and the salts sodium chloride, calcium chloride, and potassium chloride, in addition to water, so the team systematically analyzed plasma-activated synthetic versions of each component to identify which was responsible for killing cancer cells. "Only lactate demonstrated anti-tumor properties and generated hydrogen peroxide following plasma irradiation," first author Hiromasa Tanaka says. "This indicates that activated lactate increases intracellular hydrogen peroxide levels which cause apoptosis of the tumor cells."
Some cell types were not killed by treatment with PAL, suggesting it could be used as a specific tumor therapy. "PAL also appears to be safe for use in vivo," corresponding author Kae Nakamura says, "as we observed no adverse effects when PAL successfully reduced the tumor volume of mice."
Original publication
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.